https://asxan.ai/blog/atom.xml Evidence-first ingredient science hub · Cross-market regulatory framing (FDA · EFSA · ANVISA · TGA) 2026-05-30T23:02:24.418Z asxan.ai static Atom generator Educational reference · ASXAN Group · 2026 · attribution-required when excerpting https://asxan.ai/favicon.svg https://asxan.ai/og-default.svg ASXAN Editorial https://asxan.ai/about/ https://asxan.ai/blog/nad-25-year-rct-history-evidence/ 2026-05-26T00:00:00Z 2026-05-26T00:00:00Z ASXAN Editorial https://asxan.ai/about/

Quarter-century timeline of NAD+ human evidence: Forsyth 1999 CFS NADH through Zhang J 2025 meta. Includes 8 PMID-drift cases disclosed.

https://asxan.ai/blog/nmn-vs-nr-decision-tree-evidence/ 2026-05-26T00:00:00Z 2026-05-26T00:00:00Z ASXAN Editorial https://asxan.ai/about/

5-dimension framework: absorption / RCT volume / NAD+ rise / cost-regulation / safety.

https://asxan.ai/blog/reduced-nadh-vs-nmnh-evidence/ 2026-05-26T00:00:00Z 2026-05-26T00:00:00Z ASXAN Editorial https://asxan.ai/about/

NADH Tier B CFS evidence vs NMNH Tier C emerging (0 human RCT).

https://asxan.ai/blog/natural-vs-synthetic-astaxanthin-evidence-comparison/ 2026-05-25T00:00:00Z 2026-05-25T00:00:00Z ASXAN Editorial https://asxan.ai/about/

Haematococcus pluvialis natural vs synthetic chemical astaxanthin · stereochemistry / bioavailability / 25-year clinical evidence.

https://asxan.ai/blog/omega-3-evidence-history-cardiovascular-and-inflammation/ 2026-05-25T00:00:00Z 2026-05-25T00:00:00Z ASXAN Editorial https://asxan.ai/about/

DART 1989 → GISSI → VITAL → REDUCE-IT → STRENGTH chronology · 6 reverse-correction cases.

https://asxan.ai/blog/protein-source-decision-tree-whey-vs-yeast-focus/ 2026-05-25T00:00:00Z 2026-05-25T00:00:00Z ASXAN Editorial https://asxan.ai/about/

5-form protein decision tree · DIAAS framework · GLP-1 era · 5 reverse-correction cases.